Related Experiment Videos
Longitudinal study of rheumatoid arthritis patients discloses sustained elevated serum levels of soluble CD106
M N Kolopp-Sarda1, F Guillemin, I Chary-Valckenaere
1Laboratoire d'Immunologie, Faculté de Médecine & CHU Nancy, France.
Insights
Rheumatoid arthritis (RA) patients show persistently high levels of soluble CD106 (sCD106), also known as VCAM-1. This suggests sCD106 may play a role in the long-term progression of RA.
Area of Science:
- Rheumatology
- Immunology
- Biochemistry
Background:
- Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation.
- Angiogenic and adhesion molecules are implicated in RA pathogenesis and progression.
- Understanding the dynamic changes in these molecules is crucial for RA management.
Purpose of the Study:
- To investigate the longitudinal changes in serum levels of specific angiogenic and adhesion molecules in RA patients.
- To correlate these molecular changes with disease activity and severity over a 6-year period.
- To identify potential biomarkers for RA chronicity and progression.
Main Methods:
- Serum samples from 43 RA patients were collected over 6 years.
- Levels of 5 soluble glycoproteins (VEGF, CD31, CD54, CD62E, CD106) were quantified using ELISA.
- Clinical parameters of disease activity and severity were monitored concurrently.
Main Results:
- RA patients exhibited significantly elevated serum levels of soluble CD106 (sCD106/VCAM-1) compared to controls (p < 0.0001).
- Serum levels of soluble VEGF, CD31, CD54, and CD62E were normal or decreased in RA patients.
- No significant temporal trends or effects of therapeutic agents on these molecule levels were observed.
Conclusions:
- Sustained high serum concentrations of sCD106 in RA patients suggest its potential involvement in the chronic nature and progression of the disease.
- sCD106 may serve as a biomarker for RA chronicity.
- Further research is warranted to elucidate the precise role of sCD106 in RA pathogenesis.
Objective:
To appreciate the evolution of serum angiogenic and/or adhesion molecules levels during a long term follow-up of rheumatoid arthritis (RA) patients.
Methods:
Serum levels of 5 soluble adhesion/angiogenesis glycoproteins (VEGF, CD31, CD54, CD62E, CD106) were measured in Elisa in samples collected over 6 years in a cohort of 43 RA patients with monitored clinical parameters of disease activity and severity.
Results:
RA patients had significantly higher levels (p < 0.0001) of sCD106 (VCAM-1) than control subjects. Conversely, the levels of soluble VEGF, CD31, CD54 and CD62E were normal or lower than normal. No statistically significant time effect was noted. No effect either was noted as related to the therapeutic agents taken by the patients.
Conclusion:
The sustained elevated serum levels of sCD106 observed here imply that this molecule might be related to the chronicity and progression of RA.